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ABSTRACT 
                 The  present  study  has  been  designed  and  conducted  to  
investigate  the   effect   of   thyroid  diseases   on   renal   function  by  
estimation  of  the  levels of serum urea,creatinine, uric acid , calcium, 
sodium, potassium and phosphorus concentrations. 
               The  subjects   included  in  this  study  were  59  thyroid                         
dysfunction patients (hyper and hypothyroidism) before and after 
treatment. They divided into two groups: 
Group (A): untreated patients (hyper and hypothyroidism). 
Group (B): under treatment (hyper and hypothyroidism). 
              All of them were females attended in radiation and isotopes 
center Khartoum and other 15 healthy Sudanese females (group C) were 
taken as a control group.  
             Serum samples were analyzed using radioimmunoassay and 
spectrophotometer methods, the mean of serum concentration levels of 
urea showed clear increased in all patients before and after treatment but 
the means of serum concentration levels of creatinine and uric acid 
showed no differences compared to the euthyroid subjects. Also there 
was simple increased on serum concentrations of calcium, potassium and 
phosphorus levels in hyperthyroidism compared to the euthyroid 
subjects. 
             The present study showed that there is no direct effect of thyroid 
disease on renal function of Sudanese females with thyroid dysfunction. 
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 اﻟﺨﻼﺻـــــــﺔ
 هѧѧѧﺬﻩ اﻟﺪراﺳѧѧѧﺔ ﺑﻬѧѧѧﺪف ﻣﻌﺮﻓѧѧѧﺔ ﺗѧѧѧﺄﺛﻴﺮ أﻣѧѧѧﺮاض اﻟﻐѧѧѧﺪة اﻟﺪرﻗﻴѧѧѧﺔ ﻋﻠѧѧѧﻰ وﻇѧѧѧﺎﺋﻒ اﻟﻜﻠѧѧѧﻰ ﻋѧѧѧﺪتأ      
 وذﻟѧѧѧﻚ ﺑﻘﻴѧѧѧﺎس ﺗﺮآﻴѧѧѧﺰ آѧѧѧﻞ ﻣѧѧѧﻦ اﻟﻴﻮرﻳѧѧѧﺎ واﻟﻜﺮﻳѧѧѧﺎﺗﻨﻴﻦ وﺣﻤѧѧѧﺾ اﻟﻴﻮرﻳѧѧѧﻚ واﻳѧѧѧﻀﺎ ﻗﻴѧѧѧﺎس أﻣѧѧѧﻼح 
اﻟﻜﺎﻟѧѧﺴﻴﻮم واﻟѧѧﺼﻮدﻳﻮم واﻟﺒﻮﺗﺎﺳѧѧﻴﻮم واﻟﻔѧѧﺴﻔﻮر ﻓѧѧﻰ ﻣѧѧﺼﻞ اﻟѧѧﺪم ﻟﻤﺮﺿѧѧﻰ ﻣѧѧﻦ اﻹﻧѧѧﺎث ﻗﺒѧѧﻞ ﺑѧѧﺪء 
ﺷѧѧѧѧﻤﻠﺖ آѧѧѧѧﻞ ﻣﺠﻤﻮﻋѧѧѧѧﺔ (.اﻟﻤﺠﻤﻮﻋѧѧѧѧﺔ اﻟﺜﺎﻧﻴѧѧѧѧﺔ )وﺑﻌѧѧѧѧﺪ اﻟﻌѧѧѧѧﻼج ( اﻟﻤﺠﻤﻮﻋѧѧѧѧﺔ اﻷوﻟѧѧѧѧﻰ )اﻟﻌѧѧѧѧﻼج 
  :ﻧﻮﻋﻴﻦ ﻣﻦ اﻟﻤﺮﺿﻰ
ﻣﺮﺿѧѧѧѧѧѧѧѧѧѧѧﻰ اﻟﻐѧѧѧѧѧѧѧѧѧѧѧﺪة اﻟﺪرﻗﻴѧѧѧѧѧѧѧѧѧѧѧﺔ ذات اﻟﻨѧѧѧѧѧѧѧѧѧѧѧﺸﺎط اﻟﻌѧѧѧѧѧѧѧѧѧѧѧﺎﻟﻰ وﺗﻌѧѧѧѧѧѧѧѧѧѧѧﺮف ب  :اﻟﻨѧѧѧѧѧѧѧѧѧѧѧﻮع اﻻول
  .msidioryhtrepyh
وﺗﻌѧѧѧѧѧﺮف ب ( اﻟﺨﺎﻣѧѧѧѧѧﻞ )ﻣﺮﺿѧѧѧѧѧﻰ اﻟﻐѧѧѧѧѧﺪة اﻟﺪرﻗﻴѧѧѧѧѧﺔ ذات اﻟﻨѧѧѧѧѧﺸﺎط اﻟﻤѧѧѧѧѧﻨﺨﻔﺾ : اﻟﻨѧѧѧѧѧﻮع اﻟﺜѧѧѧѧѧﺎﻧﻰ 
  .msidioryhtopyh
 ﻣѧѧѧﻦ اﻹﻧѧѧѧﺎث ٥١ ﻣﺮﻳѧѧѧﻀﺔ ﺳѧѧѧﻮداﻧﻴﺔ ﺗﻤѧѧѧﺖ ﻣﻘѧѧѧﺎرﻧﺘﻬﻢ ب ٩٥      أﺟﺮﻳѧѧѧﺖ هѧѧѧﺬﻩ اﻟﺪراﺳѧѧѧﺔ ﻋﻠѧѧѧﻰ 
ﺗѧѧѧѧѧﻢ ﺗﺤﻠﻴѧѧѧѧѧﻞ ﻣѧѧѧѧѧﺼﻞ اﻟѧѧѧѧѧﺪم ﺑﺎﺳѧѧѧѧѧﺘﺨﺪام اﻟﺘﺤﻠﻴѧѧѧѧѧﻞ ( اﻟﻤﺠﻤﻮﻋѧѧѧѧѧﺔ اﻟﺜﺎﻟﺜѧѧѧѧѧﺔ  )dioryhtueاﻟﻤﻌﺘѧѧѧѧѧﺪﻟﻴﻦ 
أﻇﻬѧѧѧﺮت اﻟﻨﺘѧѧѧﺎﺋﺞ ان هﻨﺎﻟѧѧѧﻚ زﻳѧѧѧﺎدة ﻣﻠﺤﻮﻇѧѧѧﺔ . ﻰاﻟﻤﻨѧѧѧﺎﻋﻰ اﻹﺷѧѧѧﻌﺎﻋﻲ وﺟﻬѧѧѧﺎز اﻟﻄﻴѧѧѧﻒ اﻟѧѧѧﻀﻮﺋ
ﻓѧѧѧﻰ ﺗﺮآﻴѧѧѧﺰ ﻳﻮرﻳѧѧѧﺎ اﻟѧѧѧﺪم ﻓѧѧѧﻰ ﺟﻤﻴѧѧѧﻊ اﻟﻤﺮﺿѧѧѧﻰ واﻧѧѧѧﻪ ﻟѧѧѧﻴﺲ هﻨﺎﻟѧѧѧﻚ ﻓѧѧѧﺮق ﻓѧѧѧﻰ ﻣﺘﻮﺳѧѧѧﻂ ﺗﺮاآﻴѧѧѧﺰ 
آﻤѧѧѧﺎ اﺗѧѧѧﻀﺢ ان هﻨﺎﻟѧѧѧﻚ .اﻟﻜﺮﻳѧѧѧﺎﺗﻨﻴﻦ وﺣﻤѧѧѧﺾ اﻟﻴﻮرﻳѧѧѧﻚ ﻓѧѧѧﻰ اﻟѧѧѧﺪم ﻣﻘﺎرﻧѧѧѧﺔ ﺑﺎﻹﻧѧѧѧﺎث اﻟﻤﻌﺘѧѧѧﺪﻟﻴﻦ 
ﻟѧѧѧـ زﻳѧѧѧﺎدة ﺑѧѧѧﺴﻴﻄﺔ ﻓѧѧѧﻰ ﺗﺮآﻴѧѧѧﺰ آѧѧѧﻞ ﻣѧѧѧﻦ اﻟﻜﺎﻟѧѧѧﺴﻴﻮم واﻟﺒﻮﺗﺎﺳѧѧѧﻴﻮم واﻟﻔﻮﺳѧѧѧﻔﻮر ﻓѧѧѧﻰ دم ﻣﺮﺿѧѧѧﻰ ا 
   .msidioryhtue ﻣﻘﺎرﻧﺔ  ﺑﺎﻟﻤﻌﺘﺪﻟﻴﻦ msidioryhtrepyH
      أوﺿѧѧﺤﺖ اﻟﺪراﺳѧѧﺔ اﻧѧѧﻪ ﻟѧѧﻴﺲ هﻨﺎﻟѧѧﻚ ﺗѧѧﺎﺛﻴﺮ ﻣﺒﺎﺷѧѧﺮ ﻷﻣѧѧﺮاض اﻟﻐѧѧﺪة اﻟﺪرﻗﻴѧѧﺔ ﻋﻠѧѧﻰ وﻇѧѧﺎﺋﻒ 
  .اﻟﻜﻠﻰ ﻟﻤﺮﺿﻰ ﻣﻦ اﻹﻧﺎث اﻟﺴﻮداﻧﻴﺎت ذوات  اﻻﺧﺘﻼل  اﻟﻮﻇﻴﻔﻰ ﻟﻠﻐﺪة اﻟﺪرﻗﻴﺔ
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Introduction 
                The thyroid gland is located immediately below the larynx on 
each side of anterior to the trachea. It is one of the largest endocrine 
glands, normally weighing 20 to 25 grams in adults. The thyroid secretes 
two major hormones, thyroxine and tri-iodothyronine, commonly called 
T4 and T3, respectively. Both of these hormones profoundly increase the 
metabolic rate of the body. The lack of thyroid secretion usually causes 
hypothyrodism or mxyoedema and extreme excesses of thyroid secretion 
causes hyperthyroidism (Thyrotoxicosis). Thyroid secretion is controlled 
primarily by thyroid-stimulating hormone (TSH) secreted by the anterior 
pituitary gland. In most individuals the ratio of T4:T3 secreted is 20-30:1 
but on a molar basis T3 is 3-5 times more potent than 
T4.Triiodothyronine (T3) is the true hormone while T4 serves as             
a prohormone (Brian et al. ,2001). 
               Thyroid hormones also have important effects in the kidney, 
affecting both renal morphology and function. They are required for 
kidney growth, haemodynamics, salts and water metabolism. The thyroid 
hormones deficiency results in: decreased renal plasma flow (RPF), 
decreased glomerular filtration rate (GFR),impaired urinary 
concentration and dilution , influence membrane transport and electrolyte 
metabolism. Alterations in mineral metabolism in hyperthyroidism 
frequently cause calcium nephropathy which affects renal function 
adversely (Katz et al., 1975). 
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                Graves’ disease is a common cause of hyperthyroidism, an 
overproduction of thyroid hormone, which causes enlargement of the 
thyroid and other symptoms such as exophthalmos, heat intolerance and 
anxiety. In Graves’ disease there is thyrotoxicosis, and this arises   due to 
the binding of circulating antibodies to the TSH receptor, thus causing 
their unregulated stimulation. There are complications related to the 
treatment of hyperthyroidism by surgery including low calcium levels 
due to damage of the parathyroid glands. Women generally at higher risk 
of most types of thyroid diseases than men (Hurd, 2006). 
               In untreated patients of hyperthyroidism due to Graves’ disease, 
there is increase in blood urea nitrogen (BUN), primarly due to an 
increase in urea nitrogen production, secondary to excessive protein 
catabolism together with insufficient excretion of urea nitrogen. Also 
there is increase in blood urea nitrogen and serum creatinine ratio 
(Shirota, 1991).Serum uric acid was significantly elevated in patients 
with hyperthyroidism due to an increased production of uric acid that 
surmounted  the increase in clearance of uric acid (Sato et al., 1995). 
                   There was a strong correlation between the change in thyroid 
status and the change in renal function therefore the kidney is an 
important target of thyroid hormone action. However, this has not been 
studied in detail in human subjects (Hollander et al., 2005).                        
The objectives of the study: 
1- To investigate the levels of renal parameters: urea, creatinine, uric 
acid, calcium, sodium, potassium and phosphorus of hypo and 
hyperthyroid Sudanese females. 
2- To see the variations of the levels of renal parameters of hypo and 
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hyperthyroid patients. 
3- To investigate the effect of thyroid disease on renal function of 
Sudanese females. 
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 Chapter one 
Literature review 
 
                  The word “thyroid” is derived from Greek word Thyreos, 
means “A shield”. Thyroid hormones are vital signaling molecules in 
both mammals and primitive organisms. However, they were not 
discovered until around 1891 when George Murray noted improvement 
in certain myxedematous patients after administration of sheep thyroid 
extracts. The structures of the thyroid hormones proved elusive and were 
not determined until the 1920s when both thyroxine (T4) and 
triiodothyronine (T3) were shown to be iodinated derivatives of tyrosine 
(Rex et al., 1996). 
1.1  Physiological anatomy of the thyroid gland:  
               The normal adults’ thyroid gland is the largest endocrine gland, 
weighting 15-25 g and it is highly vascular. It is situated in front of the 
larynx, bilobed (right and left lobes), connected by a bridge of tissue 
called thyroid isthmus. There is sometimes a pyramidal lobe arising from 
the isthmus (Jain, 2005). 
                    The thyroid gland has a blood flow about five times the 
weight of the gland each minute, which is a blood supply as great as that 
of any other area of the body, with the possible exception of the adrenal 
cortex (Guyton, 2000). It has a large lymphatic drainage through which 
part of the stored large molecular thyroglobulin may enter the circulation. 
The thyroid is innervated by the sympathetic system which probably 
supplies only blood vessels (Cyril etal., 1982). 
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1.1.1 Histology: 
                  The thyroid gland is made of multiple acini or follicles,       
50-500µm diameter. Approximately 40 follicles are grouped together to 
form a lobule. The follicular epithelium consists of a single layer of 
cuboidal cells. The cell height of the follicular epithelium varies with the 
activity of the gland i.e. degree of stimulation of TSH, cells becoming 
columnar when active and flat when inactive. The lumen of the follicle is 
filled with a clear gelatinous pink material called colloid (thyroglobulin 
containing iodine). Thyroglobulin is a glycoprotein; molecular weight 
660kDa synthesized in the thyroid cells and is secreted into the colloid by 
exocytosis of granules. Normal serum thyroglobulin concentration is       
6 ng/ml. thyroid cells microvilli extend into the colloid and their 
functions are: collection of iodine from blood and transporting it to the 
colloid for hormone synthesis, synthesize the thyroglobulin, which is 
stored as colloid in the follicles, and remove the thyroid hormones from 
thyroglobulin and secrete them into circulation (Jain, 2005). 
1.2 Thyroid hormones: 
                   About 93% of the metabolically active hormones secreted by 
the thyroid gland are thyroxine, and 7% triiodothyronine. However, 
almost all the thyroxine is eventually converted to triiodothyronine in the 
tissues, so that both are functionally important. The functions of these 
two hormones are qualitatively the same, but they differ in rapidity and 
intensity of action. Triiodothyronine is about four times as potent as 
thyroxine, but it is present in the blood in much smaller quantities and 
persists for a much shorter time than does thyroxine (Guyton, 2000). 
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                  The signals of thyroid hormones are remarkably stable as a 
result of the long half life (6-9 days) of T4. On the other hand, T3 is more 
active than T4 and has a half life of 24-36 hours. The structures of T3 and 
T4 seen in Fig. (1) are those of hydrophobic molecules (slightly         
lipid-soluble) with limited solubility in water. Nevertheless, the 
hormones are readily absorbed intact from the intestine and may be given 
orally to patients (Rex et al., 1996). T3 and T4 are iodine containing 
amino acids, secreted by the follicular cells. They are synthesized in the 
colloid by iodination and condensation of tyrosine molecules and bound 
by peptide linkage in thyroglobulin. These hormones remain bound to 
thyroglobulin until secreted. When they are secreted, colloid is ingested 
by thyroid cells and peptide bonds are hydrolyzed discharging free T3 
and T4 into the capillaries (Jain, 2005). 
1.2.1 Functions of thyroid hormones: 
                  Thyroid hormones are required particularly for normal fetal 
growth and maturation i.e. bone maturation and for normal development 
of the central nervous system (CNS). It maintains the level of oxidative 
metabolism by stimulation oxygen consumption of most of the body 
tissues that is optimal for their normal function. It helps to regulate fat 
and carbohydrate metabolism (Jain, 2005). 
                   Thyroid is not absolutely essential for life, but in its absence 
there is poor resistance to cold, mental and physical slowing, and in 
children, mental retardation and dwarfism. Conversely, excess thyroid 
secretion leads to body wasting, nervousness, tachycardia, tremor, and 
excess heat production. Also excessive production of thyroid hormones 
causes considerable muscle weakness. Thyroid function is controlled by 
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the thyroid-stimulating hormone (TSH) of the anterior pituitary. The 
secretion of these tropic hormones is in turn regulated in part by a direct 
inhibitory feed back of high circulating thyroid hormone levels on the 
pituitary and in part via neural mechanisms operating through the 
hypothalamus (Ganong, 1975). Thyroid gland also produces calcitonin, 
(calcium-lowering hormone); secreted by Parafollical cells or "C" cells 
(Jain, 2005). 
1.3 Formation and secretion of thyroid hormones: 
                    Iodine (I2) is the raw material essential for thyroid hormone 
synthesis. (I2) sources: sea fish (richest), bread, milk and vegetables. 
Daily average intake of I2 is 500µg and daily requirement of I2 is 100-200 
µg for normal thyroid functions. Thyroid contains 5-8mg of I2, i.e. 95% 
of total  I2  content of the body. The thyroid gland stores enough thyroid 
hormones to maintain a euthyroid state for 3 months without hormone 
synthesis (Jain, 2005). About 120µg/day enter the thyroid at normal rates 
of thyroid hormone synthesis and secretion. Although the precursor for 
both T4 and T3 is tyrosine, the synthesis does not occur on the free amino 
acid, but rather on the tyrosine residues of thyroglobulin. Thyroglobulin 
is a glycoprotein that is synthesized by the thyroid follicular cells. It is 
stored inside the thyroid follicles as colloid droplets. The formation of 
thyroid hormones starts within this follicle (Rex etal., 1996). 
1.3.1 Iodide trapping mechanism (iodide pump): 
                     The first stage in the formation of thyroid hormones is 
transport of iodides from the blood into the thyroid glandular cells and 
follicles. Transport mechanism is frequently called the "iodide trapping 
mechanism" or "iodide pump". The thyroid cell is about 50mv negative 
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to the interstitial area and the colloid; it has arresting membrane potential 
of -50mv. Iodide is presumably pumped into the cell at its base against 
this electrical gradient, and then diffuses down the electrical gradient into 
the colloid. In normal gland the iodide pump concentrates the iodide to 
about 30 times its concentration in the blood (Ganong, 1975; Guyton, 
2000). The working of I- pump depends on the activity of Na+-K+ 
dependent ATPase system (which gets inhibited by ouabain) and the 
energy is provided by oxidative metabolism taking place in the cells. 
Iodide(I-) pump stimulated by TSH from anterior pituitary which 
increases I- transport into the cell and inhibited by competitive inhibition 
of number of monovalent anions(chlorate, perchlorate and thiocyanate, 
pertechnetate, periodate, bi-iodate and nitrate) compete with I- for active 
transport into the thyroid, this decreases I- uptake to the point where ratio 
of thyroid I- to plasma or serum free I- i.e. T/S ratio become 1 (the normal 
T/S ratio is 25-50:1). Also inhibited by metabolic poisons e.g. dintrite, 
cyanide etc… (Jain, 2005). 
1.3.2 Organification of thyroglobulin:  
                  The next step in thyroid hormone synthesis involves the 
covalent attachment (organification) of the iodine to thyroglobulin. 
Iodide is oxidized by hydrogen peroxide to form a positively charged 
iodine ion that reacts with specific tyrosine residues on thyroglobulin to 
produce monoiodotyrosines (MIT) within the thyroglobulin. This 
reaction is catalyzed by the enzyme thyroperoxidase. Monoiodotyrosines 
undergo a similar second reaction to form diiodotyrosine (DIT) this 
reaction is also catalyzed by thyroperoxidase (Rex et al., 1996). After 
this step comes the coupling of iodotyrosines to form thyronines. 
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Coupling occurs by the translocation of the iodophenolic ring from one 
iodotyrosine to the phenol group of another, resulting in the formation of 
a thyronine and a dehydroalanayl residue at the tyrosine that loses its 
phenolic group. The coupling of two diiodotyrosines yields T4 and the 
coupling of monoiodotyrosine to diiodoytrosine forms T3                   
(Rex et al., 1996). 
               The major hormonal product of the coupling reaction is the 
molecule thyroxine that remains part of thyroglobulin (Guyton, 2000). 
Thyroid peroxidase and coupling enzymes which form T4 and T3 are 
competitively inhibited by anti-thyroid drugs thiourylenes e.g. thiouracil 
and carbimazole (Jain, 2005). 
1.3.3 Storage and release of hormones: 
                  The thyroid gland is unusual among the endocrine glands in 
its ability to store large amounts of hormone. After synthesis of the 
thyroid hormones has run its course, each thyroglobulin molecule 
contains up to 30 thyroxine molecules and a few trioolothyronine 
molecules. In this form, the thyroid hormones are stored in the follicles in 
an amount sufficient to supply the body with its normal requirements of 
thyroid hormones for 2 to 3 months. Therefore, when synthesis of thyroid 
hormone ceases, the physiologic effects of deficiency are not observed 
for several months (Guyton, 2000). The T3 and T4 are secreted in plasma, 
T3: 4µg/day and T4: 80µg/day; remaining are traces of reverse T3 and 
other components. In thyroid cells are lysosomes whose proteases break  
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down the peptide bond to cause liberation of T3, T4, DIT and MIT into 
the cytoplasm. Iodinated T3 and T4 are deiodinated by a cell enzyme 
iodotyrosine dehalogenase and the iodide (I-) liberated is re-utilized. As 
this enzyme does attack MIT or DIT, therefore, they do not appear in 
circulation (Jain, 2005). 
1.4 Transport and action of thyroid hormones: 
                  Thyroid hormones in the blood are transported almost 
completely bound to specific binding proteins. The thyroid hormones are 
bound to three different thyroid-binding proteins; thyroid-binding 
globulin (TBG) binds about 80% of T4 and 55% of T3. TBG is a 
glycoprotein with a molecular weight of 54 kDa.TBG has a high affinity 
but low capacity for T4. Thyroid-binding prealbumin (TBPA) or Trans- 
thyretin has a moderate affinity and capacity for T4 .Albumin has low 
affinity but high capacity for T4 and T3 binding (Rex et al., 1996; Cyril 
etal., 1982). However, affinities of the proteins for T4 are such that most 
of the circulating T4 is bound TBG; only small amounts of T4 are bound 
to transthyretin and practically none to albumin (Jain, 2005). 
              The free thyroid hormones in plasma are in equilibrium with the 
protein-bound thyroid hormones in the plasma and protein-bound thyroid 
hormones in the tissues. Free thyroid hormones are added to the 
circulating pool by the thyroid. It is the free thyroid hormones in plasma 
which are physiologically active, and in all probability it is this fraction 
which inhibits the pituitary secretion of TSH. Because of the equilibrium, 
the entry of thyroid hormone in the tissues is increased whenever the 
concentration of free thyroid hormone in the plasma is elevated. The 
hormones are metabolized in the tissues, and consequently their rate of 
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metabolism is increased. Conversely, when the free thyroid hormone 
level in the plasma is decreased, the tissue uptake and rate of hormone 
metabolism is reduced (Ganong, 1975).  
                Fluctuations in binding proteins: sudden, sustained rise or fall 
in the concentration of the thyroid binding proteins in plasma can cause 
an increase or decrease in the concentration of T4 and T3; but practically 
it is not seen, because there is a corresponding increase or decrease in the 
rate of entry of free T4 and T3 into the tissues. This results in normal 
plasma concentration of the free T4 and T3. Moreover, increase or 
decrease in the concentration of T4 and T3 via anterior pituitary causes 
alteration in TSH secretion and normal concentration of free T4 and T3 is 
restored. This is the reason why the patients with elevated or decreased 
concentration of thyroid binding proteins are neither hyper nor 
hypothyroid i.e. they are euthyroid (normal clinical thyroid state). 
Thyroid binding proteins levels are increased in oestrogen treated 
patients and during pregnancy; whereas its levels are decreased by 
glucocorticoids and androgens (Jain, 2005). 
                Thyroxine (T4), the primary secretory product of the thyroid, is 
relatively inactive and is converted to the active hormone, 
triiodothyronine (T3) by the enzyme thyroxine 5-deiodinase       (Gregory, 
1994). The action of thyroid hormones is primarily the result of the 
interaction of T3 with nuclear receptors for T3 that bind to regulatory 
regions of genes (thyroid hormone-response elements) and modify their 
expression (Glass et al., 1990; Brent et al., 1991). 
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1.5 Metabolism of thyroid hormones: 
                   Thyroid hormones are deaminated and decarboxylated in 
many tissues.  Most of the T4 get deiodinated (removal of I-) to T3 and 
then it produces its physiological action. Over nutrition stimulates the 
conversion of T4 to T3. Many tissues also have the enzyme 5-deiodinase, 
which catalyzes the removal of I- from the inner ring to form reverse T3 
(rT3), an inactive compound. Formation of (rT3) is thought to be an 
adaptive mechanism to lower the basal metabolic rate during starvation 
or systemic illnesses (Jain, 2005; Rex et al., 1996). 
             About 80% of both hormones T3 and T4 are ultimately 
deiodinated and the remaining 20% is conjugated in the liver, T4 
combining more readily with glucuronic acid and T3 forming mostly the 
sulphate ester. The conjugates are secreted in the bile and undergo 
hydrolysis in the gut where the free hormone is to some extent 
reabsorbed, or (if hydrolysis occurs below the region where 
iodothyronines are absorbed) excreted in the faeces. Unbound, 
unconjugated thyroid hormones are destroyed in the body, especially in 
liver and muscle, by oxidation, deamination, decarboxylation, and 
splitting of the ether ―o ― linkage as well as deiodination. The 
deaminated products tetraiodothyroacetic acid (tetrac formed from T4) 
and triiodothyroacetic acid(triac formed from T3 ) act much more quickly 
than their parent compounds to increase O2 consumption in isolated 
tissues or in whole animals, but the biological significance of these 
metabolites is not known (Cyril et al., 1982). 
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1.6 Regulation of thyroid secretion: 
                  There are several regulating factors which help to keep 
secretion rates and serum levels of T4 and T3 within normal limits. The 
most important factors are: 
1- TSH [Thyroid stimulating hormone, thyrotropin] 
secreted by the anterior pituitary, which in turn is under 
the control of the hypothalamus through secretion of 
thyrotropin-releasing hormone (TRH). 
2- Intrinsic auto regulatory processes within the thyroid 
which modify the responsiveness to TSH. 
3- The supply of iodine in the diet (Cyril et al., 1982). 
1.6.1 Thyroid-stimulating hormone (TSH): 
                   It is a glycoprotein, secreted by the anterior pituitary, 
containing 211 amino acids, MW 31.000; biological half life 60 min, 
degraded mainly in the kidneys and to a lesser extent in the liver. The 
normal secretion rate is 110µg/day with average plasma level 2.3µIU/ml. 
Its secretion is under the control of the hypothalamus through secretion 
of TRH. The secretion is pulsatile in nature in that it starts rising towards 
the evening, peak is achieved at midnight and the secretion decreases 
during the day time (Jain, 2005). 
1.6.1.1 Mechanism of action: 
                   The effects of TSH on the thyroid cell result from activation 
of the "second messenger" cyclic adenosine mono phosphate (cAMP) 
system of the cell. The first event in this activation is the binding of TSH 
with specific TSH receptors on the basal membrane surfaces of the 
thyroid cell. This then activates adenylyl cyclase in the membrane, which 
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increases the formation of cAMP inside the cell. Finally, the cAMP acts 
as a second messenger to activate protein kinase, which causes multiple 
phosphrylations throughout the cell. The result is both an immediate 
increase in secretion of the thyroid hormones and prolonged growth of 
the thyroid glandular tissue it self (Guyton, 2000). 
1.6.1.2 Effects of TSH on the thyroid gland:  
                   TSH acts directly on the thyroid to increase secretion of 
thyroid hormones, to make the follicular cells cuboidal or columnar in 
shape, to increase the number of follicular cells (hyperplasia), to reduce 
the amount of follicular colloid and to increase the vascularity of the 
gland. Also TSH increase the number of intracellular colloid droplets, as 
the colloid droplets move into the cell lysosomes move from the base of 
the cell to fuse with the colloid droplets to form phagolysosomes from 
which proteolytic enzymes are released to split off the thyroid hormones 
from the thyroglobulin molecule. The T4 and T3 so released diffuse from 
the cell into the capillary blood. TSH not only stimulates the secretion of 
stored thyroid hormones from the follicular colloid but it also promotes 
synthesis of fresh thyroid hormones by increasing iodide transport into 
the thyroid cells and by enhancing organic binding of iodine to tyrosine 
and the subsequent coupling to form thyroid hormones on the surface of 
the thyroglobulin molecule. Other effects of TSH on thyroid follicular 
cell activity include increased O2 consumption, increased glucose and 
fatty acid utilization, CO2 production, increased phospholipid formation 
(to help fresh membrane after endocytosis of colloid droplets), increased 
RNA and protein synthesis, and after 48 hours, increased DNA content 
which precedes cell mitosis (Cyril et al., 1982). 
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                   Increased TSH secretion or prolonged administration of TSH 
produces goiter (enlargement of thyroid gland); and removal of anterior 
pituitary causes atrophy of the thyroid gland (Jain, 2005). 
1.6.1.3 Control of TSH secretion: 
                   The release of TSH by the anterior lobe of the pituitary gland 
is regulated by the hypothalamus and via feed back mechanism. Anterior 
pituitary secretion of TSH is controlled by a hypothalamus hormone, 
thyrotropin-releasing hormone (TRH), which is secreted by nerve 
endings in the median eminence of the hypothalamus. From the median 
eminence, the TRH is then transported to the anterior pituitary by a way 
of the hypothalamic-hypophysial portal blood. TRH has been obtained in 
pure form. It is a simple substance, a tripeptide amide pyroglutamyl-
histidyl-proline amide. TRH directly affects the anterior pituitary gland 
cells to increase their output of TSH. When the blood portal system from 
the hypothalamus to the anterior pituitary gland becomes blocked, the 
rate of secretion of TSH by the anterior pituitary decreases greatly but is 
not reduced to zero. The molecular mechanism by which TRH causes the 
TSH-secreting cells of the anterior pituitary to produce TSH is first bind 
with TRH receptors in the pituitary cell membrane. This in turn activates 
the phospholipase second messenger system inside the pituitary cells to 
produce large amounts of phospholipase C, followed by a cascade of 
other second messengers, including calcium ions and diacyl glycerol, 
which eventually leads to TSH release (Guyton, 2000). 
                   The stimulate action of TRH on pituitary thyrotrophs is 
competitively inhibited by T4 or T3. This is the basis for the negative 
feedback control exerted by thyroid hormones on the secretion of TSH by 
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the adenohypophysis. The deiodination of T4 to T3 occurs in many tissues 
but is greatest in the pituitary, so it seems likely that T3 is the main 
hormone producing this negative feed back. There is no clear cut 
evidence that thyroid hormones influence the secretion of TRH     
(Burger and Patel, 1977). 
                   Many other factors, intrinsic and extrinsic, enter into the 
control of TSH and thyroid function. Of great importance is the 
availability of iodide, mainly through dietary source. This affects the 
total amount of thyroid hormone formed as well as the ratio of T4 to T3, 
and thus determines the output of TSH. In iodide-deficient areas the out 
put of thyroid hormone is low and TSH secretion is high; goiter results 
from this prolonged stimulation. In addition, large doses of iodide have 
direct inhibitory effects on the thyroid gland, on the binding of the 
element within the gland and, most marked, on the pinocytic processes 
that lead to enhanced engulfment of colloid and secretion of T4 and T3. 
This effect is exploited in the treatment of thyrotoxic crises     
(Weatherall et al., 1984). 
1.7 The renal functions:  
                   The kidney has many functions such as the regulation of the 
osmotic pressure of the body fluids. It regulates the volume of the 
extracellular fluid (ECF) by the excretion of sodium and water. Also it 
regulates the individual concentrations of numerous electrolytes in the 
ECF, including sodium, potassium, hydrogen, calcium, magnesium, 
chloride, sulfate and phosphate ions. The kidney eliminates waste 
products of metabolism, such as urea, uric acid and creatinine. Also 
eliminate foreign compounds from the body e.g. drugs (Selkurt, 1982).  
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1.7.1 Blood urea nitrogen (BUN):   
                   Urea (BUN) is a relatively non-toxic substance made by the 
liver as a means of disposing of ammonia from protein metabolism 
(normal BUN is 8-25 mg\dl). If the glomerular filtrate is flowing slowly 
through the proximal tubule, urea tends to be passively reabsorbed and 
return to the blood stream. Blood urea levels are quite sensitive indicators 
of renal disease (Ed, 2007).  
1.7.2 Creatinine level:   
                   Measuring serum creatinine is a useful and inexpensive 
method of evaluating renal dysfunction. Creatinine is a non-protein waste 
product of creatine phosphate metabolism by skeletal muscle tissue. 
Creatinine production is continuous and it is proportional to muscle mass. 
Creatinine is freely filtered and therefore the serum creatinine level 
depends on the glomerular filtration rate (GFR). Renal dysfunction 
diminishes the ability to filter creatinine and the serum creatinine rises. If 
the serum creatinine level doubles, the GFR is considered to have been 
halved. A three fold increase is considered to reflect a 75% loss of kidney 
function. 
Reference values for serum creatinine: 
             Adult males: 0.8-1.4 mg/dl 
             Adult females: 0.6-1.1 mg/dl 
Values are slightly higher in males due to larger muscle mass. 
            The only important pathological condition that causes a 
significant increase in the serum creatinine level is damage to a large 
19 
number of nephrons. Unlike the BUN, the serum creatinine level is not 
affected by hepatic protein metabolism. The serum creatinine level does 
not rise until at least half of the kidney's nephrons are destroyed or 
damaged. Because creatinine levels rise and fall more slowly than BUN 
levels, creatinine levels often preferred to monitor renal function on a 
long-term basis (rnceus.com/renal/renal creat.html). 
1.7.3 Uric acid levels:  
                   This breakdown product of purine metabolism is filtered by 
the golmeruli and both reabsorbed and secreted by the renal tubules. 
Serum levels are highly variable from day to day. Indications for 
ordering this test include suspected gout and suspect uric acid 
nephropathy. However, it is generally measured as part of an automated 
chemistry profile (Ed, 2007). 
1.7.4 Calcium, phosphate ions and sodium, potassium electrolytes:  
                   Calcium (Ca++), a cation or positive electrolyte that affects 
neuromuscular performance and contributes to skeletal growth and blood 
coagulation, whereas phosphate (HPo4) is a negative electrolyte that 
impacts metabolism and regulates acid base balance and calcium levels. 
Also sodium (Na+) and potassium (K+) are positively charged electrolytes 
that help to balance fluid levels in the body and regulate neuromuscular 
function and osmotic pressure (Paula, 2003). 
1.8 Thyroid diseases:  
                   Diseases of the thyroid gland are manifested by qualitative or 
quantitative alterations in hormone secretion, enlargement of the thyroid 
(goiter), or both insufficient hormone secretion results in the syndrome of 
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hypothyroidism or myxedema, in which decreased caloric expenditure 
(hypometabolism) is a principle feature. Conversely, excessive secretion 
of active hormone results in hypermetabolism and other features of a 
syndrome termed hyperthyroidism or thyrotoxicosis (Delange, 1974; 
Braunwald et al., 1987).The thyroid gland plays an important role in 
tissue metabolism and development. It secretes T4 and T3, both have 
systemic effects. Abnormal thyroid hormone levels lead to hypothyroid 
and hyperthyroid states. Inadequate thyroid hormone during development 
leads to congenital hypothyroidism (also known as cretinism) with 
associated irreversible brain damage (Gabriel, 2006). 
1.8.1 Goitre: 
                   Goitre refers to any enlargement of the thyroid gland, with or 
without disturbance of function. There are many causes of goitre:  
1- Physiological goitre: this is a diffuse moderate 
enlargement due to increased demand for thyroid 
hormones, as in puberty, pregnancy, lactation and 
chronic exposure to cold. 
2- Iodine deficiency: dietary iodine deficiency over a long 
time gives rise to simple goitre. This usually occurs in 
populations living in highlands far from the sea, where 
rainfall washes away the iodine content of the soil. The 
condition is endemic. Several members of the family are 
usually affected. The size of the gland can be extremely 
large, but there is no disturbance of function.  
3- Hereditary defect in thyroid hormone synthesis: this 
may be due to hereditary deficiency of any of the 
21 
enzymes concerned with thyroid hormone synthesis. 
Deficiency of these enzymes may lead to iodide trapping 
defect, iodine organification defect, iodotyrosine 
coupling defect or deiodination defect. 
Consequently, low circulating thyroid hormone levels 
lead to increased production of TSH, which causes 
hypertrophy and hyperplasia of the gland. 
                   4-  Excessive  intake  of  goitrogens,  e.g:  drugs  such  as  
                         sulphonamides, thiocarbamides, perchlorate, can suppress 
                         thyroid  hormone synthesis and  lead to goitre  formation        
                       (Sukkar et al., 2000). 
1.8.2 Hypothyroidism: 
                   Hypothyroidism is the term for deficient thyroid hormone 
secretion by the thyroid gland. By far the commonest cause of 
hypothyroidism is failure of thyroid gland itself, known as primary 
hypothyroidism. This is usually due to autoimmune disease-either 
spontaneous or after destructive therapy of Graves' disease (Robert and 
Anthony, 1997). The condition is particularly prevalent in older women. 
Other important causes include congenital thyroid disorders, previous 
thyroid surgery and irradiation, drugs such as lithium carbonate and 
amiodarone, and pituitary and hypothalamic disorders. Worldwide, 
dietary iodine deficiency remains an important cause. Hypothyroidism 
can present with nonspecific constitutional and neuropsychiatric 
complaints, or with hypercholesterolaemia, hyponatraemia, 
hyperprolactinaemia, or hyperhomocysteinaemia. Severe untreated 
hypothyroidism can lead to heart failure, psychosis, and coma. The 
22 
diagnosis is confirmed or excluded by measurements of serum 
thyrotropin and free thyroxine (Caroline et al., 2004). 
                   Hypothyroidism can be classified on the basis of its time of 
onset (congenital or acquired), the level of endocrine dysfunction 
responsible (primary or secondary, also termed central, hypothyroidism), 
and its severity [overt (clinical) or mild (sub clinical)]. In patients with 
primary hypothyroidism, in whom serum TSH is elevated, the distinction 
between overt and mild hypothyroidism can be defined biochemically by 
whether the serum free thyroxine concentration is below or within the 
reference range, respectively. The term myxoedema is now usually 
reserved for cases of overt hypothyroidism that are severe or 
complicated, or both. Cretinism refers to the syndrome of mental 
retardation, deafness, short stature, and characteristic facial      
deformities occurring with untreated congenital hypothyroidism                    
(Caroline et al., 2004). 
1.8.3 Hyperthyroidism:   
                   Hyperthyroidism is a pathological syndrome in which tissue 
is exposed to excessive amounts of circulating thyroid hormone. The 
most common cause of this syndrome Graves' disease, followed by toxic 
multinodular goitre, and solitary hyper functioning nodules. Autoimmune 
postpartum and sub acute thyroiditis, tumours that secrete thyrotropin, 
and drug-induced thyroid dysfunction, are also important causes. The 
diagnosis of hyperthyroidism is generally straight forward, with raised 
serum thyroid hormones and suppressed serum thyrotropin in almost all 
cases. Appropriate treatment of hyperthyroidism relies on identification 
of the underling cause. Antithyroid drugs, radioactive iodine, and surgery 
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are the traditional treatments for the three common forms of 
hyperthyroidism. β-adrenergic blocking agents are used in most patients 
for symptomatic relief, and might be the only treatment needed for 
thyroiditis, which is transient. The more unusual causes of 
hyperthyroidism, including struma ovarii, thyrotropin secreting tumours, 
choriocarcinoma, and amiodarone-induced thyrotoxicosis are, more often 
than not, a challenge to diagnose and treat (Cooper, 2003). 
                   Thyrotoxicosis is used to refer to any condition in which 
there is an excessive amount of circulating thyroid hormone, irrespective 
of whether the hormone leaks from a damaged gland (thyroiditis), is 
secreted by the gland (Graves' disease), or is exogenous (factitious 
thyrotoxicosis).Other indicators of hyperthyroidism include osteoporosis, 
hypercalcaemia, congestive heart failure, a trial fibrillation, muscle 
weakness, amenorrhoea. Hypercalcaemia is present in about 10% of 
patients, because of increased bone turnover and subsequent suppression 
of parathyroid hormone in serum (Cooper, 2003). 
1.8.4 Graves' disease: 
                   Graves' disease, named after Robert J. Graves, MD, Cira 
1830s, is an autoimmune disease characterized by hyperthyroidism due 
to circulating autoantibodies. Thyroid-stimulating immunoglobulins 
(TSIs) bind to and activate thyrotropin receptors, causing the thyroid 
gland to grow and the thyroid follicles to increase synthesis of thyroid 
hormones. Graves' disease, along with Hashimoto thyroiditis is classified 
as an autoimmune thyroid disorder. Direct proof of an autoimmune 
disorder that is mediated by autoantibodies is the development of 
hyperthyroidism in healthy subjects by  transferring  thyrotropin  receptor  
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Fig.3. Pathophysiologic mechanisms of Graves disease relating 
thyroid-stimulating immunoglobulins to hyperthyroidism and 
ophthalmopathy. T4 is levothyroxine. T3 is triiodothyronine 
(Sai-ching etal., 2005) 
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Fig.4. Graves disease . Varying degrees of manifestations of 
Graves  Ophthalmopathy (Sai-ching etal., 2005). 
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 antibodies in serum from patients with Graves' disease and the passive 
transfer of thyrotropin receptor antibodies to the fetus in pregnant woman 
(Sai-Ching et al., 2005). 
                   In Graves' disease, the eyeball may begin to stick out 
(exophthalmas), causing eye irritation and tearing. Risk factors are being 
a woman over 20 years old, although the disorder may occur at any age 
and may affect men as well. Physical examination shows an increased 
heart rate. Examination of the neck may show thyroid enlargement 
(goitre). Beta-blockers such as propranolol are often used to treat 
symptoms of rapid heart rate, sweating, and anxiety until the 
hyperthyroidism is controlled (Hurd, 2006). 
                   Doctors do not know what causes immune system to attack 
thyroid gland. However, they believe a combination of factors, including 
heredity, sex, age and stress, may determine likelihood of developing 
Graves' disease (Mayo, 2005). 
1.9 Effect of thyroid disease on renal function: 
                   Thyroid hormones (thyroxine T4; triiodothyronine, T3) play 
an important role in kidney growth and in the maintenance of many of its 
functions. In general, most parameters of renal function are enhanced in 
hyperthyroid patients and depressed in hypothyroidism. These alterations 
are corrected when patients become euthyroid (Adrian et al., 1977). 
There was a strong correlation between the change in thyroid status and 
the change in renal function as a result of therapy expressed as serum 
creatinine and estimated glomerular filteration rate (GFR) by Hollander 
and other scientists (Hollander et al., 2005). 
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                   Thyroid deficiency results in decreased renal plasma flow 
and glomerular filtration rate and in impaired urinary concentration and 
dilution. Thyroid hormone also influence membrane transport and 
electrolytes metabolism, and alteration in mineral metabolism in 
hyperthyroidism frequently cause calcium nephropathy which affects 
renal function adversely. The kidney plays an important role in the 
peripheral metabolism of iodine and thyroid hormones. The pathogenesis 
of these alterations is currently under active investigation                     
(Katz et al., 1975). 
1.9.1 Effect of thyroid disease on blood urea nitrogen and creatinine: 
                   In studies on the renal handling of urea nitrogen (BUN), 
creatinine(CR), water and electrolytes in hyperthyroid patients with 
Graves' disease show  the blood urea nitrogen and serum creatinine ratio 
[BUN/ CR]  significantly elevated  and returned to normal after 
treatment. Serum electrolytes were not significantly different in patients 
compared to the controls and the differences were not statistically 
significant (Shirota, 1991). 
                   Renal function impairment and electrolytes disorders in 
hypothyroidism are frequently subtle and rarely observed in clinical 
practice. To assess the extent of these defects, serum concentration of 
electrolytes and glomerular filtration rate were estimated by  
(Montenegro etal., 1996) before and after thyroid replacement therapy in 
41 patients with primary hypothyroidism. All patients had decreased 
glomerular filtration rates and 22 patients had high serum creatinine 
levels. Although a relationship between creatinine clearance and serum 
thyrotropin-stimulating hormone was not found, a weak correlation 
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between age and serum creatinine concentration was observed. 
Hyponatremia was documented in 45% of 22 patients with elevated 
serum creatinine but in only 21% of 19 patients with normal creatinine. 
All of these defects were corrected by treatment with thyroid hormones. 
                   They concluded that creatinine clearance was slightly 
decreased in all patients with hypothyroidism, this decrease being more 
noticeable in elderly patients. The greater the impairment in renal 
function, the more common was the occurrence of hyponatremia 
(Montenegro et al., 1996).  
1.9.2 Effect of thyroid disease on uric acid metabolism: 
                   The effects of hyperthyroidism on uric acid metabolism were 
investigated. Serum uric acid was significantly elevated in patients with 
hyperthyroidism, and the elevation correlated well with serum T4 before 
treatment as a group and during treatment in each patient. A significant 
elevation of serum uric acid was not present in patients with a transient 
mild thyrotoxicosis due to sub acute thyroiditis. Serum uric acid was 
significantly decreased in patients with hypothyroidism. Renal excretion 
of uric acid clearly increased in hyperthyroid patients, and clearance of 
uric acid (CUA) also increased. The increase in CUA corresponded to the 
increase in renal plasma flow (RPF). A significant inverse correlation 
between CUA and serum uric acid concentration was present in 
hyperthyroid patients as in normal controls, indicating that the renal 
handling of uric acid in the tubule affected uric acid excretion           
(Sato et al., 1995).  
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1.9.3 Effect of thyroid disease on water and mineral metabolism: 
                   Thyroid hormones have a diuretic effect. There is an increase 
in the glomerular filteration rate (GFR) and an increase in renal excretion 
of sodium and calcium. Because of their catabolic effect on protein, 
potassium, creatine and uric acid, excretion is also increased         
(Sukkar et al., 2000). 
             In study of renal sodium and water handling in hypothyroid 
patients: the role of renal insufficiency by (Allon etal., 1990), tubular 
function in hypothyroid patients was compared with that in patients with 
chronic renal failure and in normal subjects. The hypothyroid and the 
chronic renal failure patients were selected to have similar reductions in 
glomerular filtration rate. The changes in tubular handling of sodium 
were not different in the hypothyroid and the chronic renal failure 
patients. The results suggest that the abnormalities in tubular sodium and 
water handling in hypothyroid patients are comparable to those present in 
other patients with a similar degree of insufficiency. Thus, the tubular 
abnormalities in hypothyroidism maybe a consequence of the associated 
decrease in glomerular filtration rate (Allon et al., 1990). 
                   In other study by (Se et al., 2007), their findings showed 
significantly higher values of serum calcium and phosphate in Graves' 
disease. Also (Inagaki et al., 2007), reported that hypothyroidism can 
result in a decrease in the conversion of cortisol to cortisone that is 
sufficient to cause hypertension and low serum potassium.  
                   In conclusion, renal function is profoundly influenced by 
thyroid status and the purpose from this study is to determine these 
alterations.   
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  Chapter two 
Materials and Methods 
2.1 Subjects: 
          Subjects included in this study were 59 thyroid dysfunction 
patients (hyper and hypothyroidism) before and after treatment. Group A 
(untreated), group B (under treatment), with age between (17-72) years 
from females patients attending in radiation and isotopes center 
Khartoum from (Radio immunoassay-laboratory) (RIA) and other 15 
healthy Sudanese females (group C) were taken as a control group. 
Samples were collected and analyzed during the period from 8/4/2007 to 
28/10/2007. 
Group A: patients in this group were divided into two sub-groups: a-1 
and a-2 
a-1: untreated patients with hyperthyroidism. 
a-2: untreated patients with hypothyroidism. 
Group B: patients in this group were divided into two sub-groups: b-1 
and b-2 
b-1: treated patients with hyperthyroidism. 
b-2: treated patients with hypothyroidism. 
Group a-1: 
          Untreated patients with hyperthyroidism: 17 Sudanese individuals, 
that are diagnosed by physicians as patients of hyperthyroidism were 
employed in this investigation. They include adult females. 
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Group a-2: 
         Untreated patients with hypothyroidism. This group consisted of 10 
untreated hypothyroidism patients including adult females. 
Group b-1: 
         Treated patients with hyperthyroidism. This group consisted of 16 
treated hyperthyroidism patients including adult females. 
Group b-2: 
         Treated patients with hypothyroidism. 16 Sudanese individuals 
diagnosed as patients of hypothyroidism. They include adult females. 
2.2 Materials: 
2.2.1 Blood samples: 
          A venous blood samples from each patient (5ml) and control was 
obtained using disposable syringes without anticoagulant, then allowed to 
clot. Centrifuged at 5000 r.p.m for 10 min. to separate serum from blood 
cells. Serum is kept into plain containers at -20 C0 till it is used for 
determination of serum T3, T4, TSH, urea, creatinine, uric acid, calcium, 
phosphate, sodium and potassium electrolytes. 
2.2.2 Equipments: 
• Disposable polystyrene tubes. 
• Micropipettes with disposable tips (50, 200, 500 µl and 
1ml). 
• Vortex type mixer. 
• Magnetic separator. 
• Water bath or oven set at 37C0. 
• Gamma counter suitable for measuring iodine 125. 
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• Absorbent blotting paper. 
• Flame photometer 410. 
• Tubes, centrifuge tubes and cuvettes. 
• Analyzer (RA-50) chemical analyzer. 
2.3 Reagents and chemicals: 
2.3.1 Specific reagents for hormones:  
             All immunoradiometric assay (IRMA) and radioimmunoassay 
(RIA) specific reagents for measurement of serum hormones. The 
reagents included: tracers, standards, antibodies and separation reagent 
for different hormones. 
2.4 Methods: 
2.4.1 Estimation of T4: 
            T4 was quantitatively measured in sera of all subjects by RIA 
method. 
   2.4.1.1 Principle: 
             The T4 RIA method depends on the competition between iodine- 
125 labeled T4 and T3 contained in standards or in specimens to be 
assayed, for a fixed and limited number of T4 antibody binding sites. 
After the incubation, the amount of iodine-125 labeled T4 bound to the 
antibody is inversely related to the amount of T4 present in the sample. 
             In the antibody suspension of this kit the antibody is covalently 
bound to magentiable particles. Separation of the antibody bound fraction 
is achieved by magnetic separator and decanting the supernatant. By 
measuring the proportion of iodine-125 labeled T4 bound in the presence 
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of reference standards containing various known amounts of T4, the 
concentration of T4 present in unknown samples can be interpolated. 
2.4.1.2 Contents of kit: 
1- One bottle (148 kBq, 4 µCi) T4 solution (55ml, red) in barbitone 
buffer with bovine serum albumin and ANS (8-anillino-1-naphtalene 
sulfonic acid). 
2- One bottle T4 antibody suspension (55ml) with antimicrobial agent. 
3- Six vials T4 standards: pipette 1ml of distilled water into each vial of 
T4 standards for reconstitution and stand for 5 min. the concentrations are 
0, 20, 40, 80, 160, 240 ng/ml. 
4- Pack insert. 
2.4.1.3 Preparation of reagents for assay: 
2.4.1.3 a T4 antibody suspension: 
             The antibody reagent should be thoroughly mixed by gentle 
shaking and swirling to sure a homogeneous suspension. 
2.4.1.3 b storage instructions: 
             Store kit at 2-8 C0. 
2.4.1.4 Assay procedure: 
            The order of the steps was followed exactly  
T(µl) Standards(µl) Unknown(µl)  
Standard serum - 50 - 
  Unknown serum     - - 50 
     I125 –T4        500 500 500 
T4antibody suspension - 500 500 
    Vortex mixed and incubated at 37C0 for 45min. magnetically separated,  
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     Supernatant discarded and counted 
1- Assay tubes were labeled and arranged in the assay rack. 
2- 50 µl aliquots of the standards or samples were pipetted into the 
prelabelled tubes. 
3- 500 µl (I125) thyroxin solution (red) was dispensed into each tube. 
4- 500 µl T4 antibody suspension was dispensed into the prelabeled 
tubes. 
5- The tubes were thoroughly mixed using a vortex, and then 
incubated at 37C0 for 45min. 
6- The tube rack was placed on the magnetic separator and allowed to 
stand for 10 min. the supernatant was decanted and the separator 
was kept inverted, the tube was on a pad of absorbent paper and 
allowed to drain for 5min. 
7- All the tubes were counted in a suitable gamma counter. 
2.4.1.5 Calculation of results: 
        Results can be calculated using lin-log plotting. 
Lin-log plotting: 
1- The count (B) for each of the standards and unknowns were 
expressed as a percentage for the mean counts of the zero 
standards (B0). The background counts were subtracted if 
significant. 
B/ B0 % ‗ B of standard or unknown × 100% 
                  B0                    
      2-   The percentage values obtained for the T4 concentration were  
             plotted  on  lin-log graph  paper and  a standard  curve  was  
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            constructed. 
      3- Read the T4 concentration directly from the curve for each of the 
         unknown samples. 
2.4.2 Estimation of T3:  
      T3 was measured by RIA, which is an assay used for the quantitative 
measurement of T3 in human serum to aid in the differential diagnosis of 
thyroid disease. 
2.4.2.1 Principle of the method: 
      It is the same principle of the T4 method. 
2.4.2.2 Contents of the kit: 
      1- One bottle (148kBq, 4µ ci) [I125] T3 solution (55ml, red) in 
barbitone buffer with bovine serum albumin and ANS (8-anilino-
naphtalene sulfonic acid). 
      2- One bottle T3 antibody suspension (55ml) with antimicrobial 
agent. 
     3- Six vials T3 standards in human serum with antimicrobial agent, 
nominally 0, 0.5, 1.0, 2.0, 4.0, 8.0 ng T3/ml. 
     4- One bottle NSB reagent (5ml) for the determination of nonspecific 
binding, with antimicrobial agent. 
    5- Pack insert. 
2.4.2.3 Preparation of reagents for assay: 
      They are the same of T4 preparation reagents. 
2.4.2.4 Assay procedure: 
      The order of the steps was followed exactly. 
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Total T3 RIA kit-assay protocol 
 Standard ng T3/ml                           unknowns  
    NSB 0 0.5 1.0 2.0 4.0 8.0    
Tube number 1-2 3-4 5-6 7-8 9-10 11-12 13-14 15-16 17-18 19-20 
Standard serum 50٭ 50 50 50 50 50 50    
Unknown serum - - - - - - - 50 50 50 
[I125] T3 500 500 500 500 500 500 500 500 500 500 
NSB 
Reagent  
500 - - - - - - - - - 
  T3 antibody 
suspension  
- 500 500 500 500 500 500 500 500 500 
                                                  Vortex mixed 
                                           Incubated at 37C0 for 60 min. 
                                          Magnetically separated, supernate        
                                          Discarded and counted   
All volumes are expressed in micro liters 
٭ Zero standard was used for the NSB reagent tubes. 
       1- Assay tubes were labeled and arranged in the assay rack. 
       2- 50µl aliquots of the standards or samples were pipetted into the 
prelabelled tubes. Zero standards were used for NSB reagent tubes which 
are recommended for logit-log plotting but are not required for lin-log 
plotting. 
       3- 500 µl [I125] T3 solution (red) was dispensed into each tube. 
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       4- 500 µl T3 antibody suspension or NSB reagent was dispensed into 
the prelabelled tubes. 
       5- The tubes were thoroughly mixed using a vortex, and then 
incubated at 37C0 for 60 min. 
       6- The test tube rack was placed on the magnetic separator and 
allowed to stand for 10 min. the supernatant was decanted and the 
separator was kept inverted, the tube was placed on a pad of absorbent 
paper and allowed to drain for 5 min. 
       7- All the tubes were counted in a suitable gamma counter. 
2.4.2.5 Calculation of results: 
       Results can be calculated using lin-log plotting. 
 Lin-log plotting: 
       1- The counts (B) for each of the standards and unknowns were 
expressed as a percentage of the mean counts of the zero standards (B0). 
The background counts were subtracted if significant. 
             B/ B0% = B of standard or unknown/ B0 × 100% 
       2- The percentage values obtained for the T3 standards were plotted 
against the T3 concentration on lin-log graph paper and a standard curve 
was constructed. 
       3- Read the T3 concentration directly from the curve for each of the 
unknown samples. 
2.4.3 Estimation of TSH: 
        This assay is used for the quantitative determination of human TSH 
in serum with magnetic separation reagent. 
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2.4.3.1 Principle of the method: 
        CIAE TSH IRMA kit utilizes a two-site sandwich 
immunoradiometric assay for the measurement of TSH in human serum. 
This involves the reaction of TSH present in serum with monoclonal and 
polyclonal antibody. The monoclonal antibody is labeled with I125 as 
tracer (I125- Mc Ab) and the polyclonal antibody is coupled to magnetic 
iron oxide particles (Pc Ab<M>). The formed I125 –Mc Ab-TSH-Pc 
Ab<M> complex (sandwich) is separated from unbound tracer by placing 
the assay tubes in the magnetic separator and decanting supernatant. The 
radioactivity of tracer in the tubes is directly proportional to the 
concentration of TSH in the specimens. 
2.4.3.2 Contents of magnetic TSH IRMA kit: 
? One vial I125 –anti-TSH (monoclonal) solution red. 
? One vial magnetic TSH antibody (polyclonal) 
suspension. 
? Seven vials TSH standards A B C D E F G lyophilized. 
? One vial concentrated wash buffer. 
2.4.3.3 Preparation for assay: 
1- 1.0 ml of distilled water was pipetted into each of the standard    
vials for reconstitution. 
2- All reagents and serum samples were allowed to reach room 
temperature (18-25C0). 
3- The magnetic TSH antibody suspension was resuspended by gentle 
mixing. A magnetic stirrer should not be used for this purpose. 
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4- Wash buffer was made by adding concentrated wash buffer (20ml) 
to 180ml distilled water. 
2.4.3.4 Assay procedure: 
1- 200µl of standards, controls and unknown serum samples were 
added to prelabelled tubes.  
2- 50µl of I125-anti-TSH solution was added to each tube including 
total count tubes. The solution was mixed gently. 
3- Incubated for one hour at 37C0. 
4- 500 µl of well mixed antibody suspension was added. The solution 
was mixed gently. 
5- Incubated for one hour at room temperature (18-25C0). 
6- Test tube rack was placed on magnetic separator and allowed to 
stand for 10 min. the supernatant was decanted and the rack was 
removed from separator. 
7- One ml of wash buffer was added and mixed using a vortex. 
8- Test tube on magnetic separator was replaced and allowed to stand 
for 10 min. the supernatant was decanted and drained thoroughly 
on an adsorbent paper. This was repeated using 1ml wash. 
9- All tubes were counted for a minimum of one minute. 
2.4.3.5 Calculation of results: 
 
2.4.3.5.1 Manual calculation of results: 
1- The count rates for each standard tube were plotted against 
the TSH concentration on semi-log graph paper (or log-log 
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graph paper). The best curve through the mean of duplicate 
points drawn, rejecting grossly aberrant counts. 
2- The mean count rate for each unknown was calculated and the 
TSH concentration was read from the standard curve. 
2.4.3.5.2 Computerized calculation of results:   
       Good quality IRMA curve fit programs should be suitable for 
calculating results. 
2.4.4 Estimation of renal parameters: 
2.4.4.1 Estimation of urea: 
                 Urea was measured according to Berthelot-Enzymatic 
colorimetric method (Tabacco etal., 1979). 
2.4.4.1.1 Principle of the method: 
       Urea in the sample originates, by means of the coupled reactions 
described below, a colored complex that can measured by 
spectrophotometry. 
Urea+ H2O Urease 2NH4++ CO2 
NH4++ salicylate+NaClO  nitroprusside   Indophenol 
2.4.4.1.2 Reagents composition: 
Reagents A1: 
? Sodium salicylate           62mmol/L 
? Sodium nitroprusside     3.4mmol/L 
? Phosphate buffer             20mmol/L 
? PH                                   6.9 
      Reagents A2: 
• Urease >    500U/ml 
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Reagents B: 
? Sodium hypochlorite  7mmol/L 
? Sodium hydroxide      150mmol/L 
Reagents S:  
? Glucose/urea/creatinine standard. Glucose 100mg/dl, 
urea 50mg/dl, creatinine 2mg/dl 
2.4.4.1.3 Reagents preparation: 
       Reagent (B) and standard (S) were provided ready to use. 
       Reagent (A): the contents of one reagent A2 vial transferred into a 
reagent A1 bottle mixed thoroughly. Other volumes should be prepared 
in the proportion: 1ml reagent A2 + 24ml reagent A1. Stable for 2 
months at 2-8C0. 
2.4.4.1.4 Procedure: 
       1- The reagents bring to room temperature. 
       2- Pipetted into labeled test tubes. 
 Blank Standard Sample 
Urea standard - 10µl - 
Sample - - 10 µl 
Reagent(A) 1.0ml 1.0ml 1.0ml 
        3- Mixed thoroughly and incubated the tubes for 10min. at room 
temperature (16-25C0) or for 5min. at 37C0.  
        4- Pipetted:  
 Blank Standard Sample 
Reagent (B) 1.0ml 1.0ml 1.0ml 
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       5- Mixed thoroughly and incubated the tubes for 10 min. at room 
temperature (16-25C0) or for 5 min. at 37C0. 
       6- The absorbance (A) of the standard and the sample were read at 
600nm against the blank. The colour was stable for at least 2 hours. 
2.4.4.1.5 Calculation: 
       The concentration of urea in the sample was calculated using the 
following general formula: 
 
 
2.4.4.2 Estimation of creatinine: 
         Creatinine was measured according to the Jaffe-Slot reaction 
method (Tietz etal., 1999). 
2.4.4.2.1 Principle of the method: 
       Creatinine in the sample reacts with picrate in alkaline medium 
forming a colored complex. The complex formation rate is measured in a 
short period to avoid interferences. 
2.4.4.2.2 Reagents composition: 
       Reagents A: 
? Sodium hydroxide   0.4mol/l 
? Detergent 
       Reagents B: 
? Picric acid     25mmol/L 
       Reagents S: 
? Glucose standard     100mg/dl 
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? Urea standard           50mg/dl 
? Creatinine standard  2mg/dl(177µmol/L) 
2.4.4.2.3 Reagents preparation: 
? Standard reagents: Ready to use. 
? Working reagents: Mixed equal volumes of reagent A 
and B. mixed thoroughly. Stable for one month at       
2-8 C0. 
2.4.4.2.4 Procedure: 
1- The working reagent and the photometer were brought at                 
37 C0. 
2-Pipetted into a cuvette: 
          Working reagent             1.0ml 
          Standard (S) or sample   1.0ml 
3- Mixed and inserted cuvette into the photometer and started 
stop watch. 
4- Recorded the absorbance at 500nm after 30 sec. (A1) and after 
90 sec. (A2). 
2.4.4.2.5 Calculation: 
       The creatinine concentration in the sample was calculated using the 
following general formula: 
 
2.4.4.3 Estimation of uric acid: 
        Uric acid was measured according to dichlorophenolsulfonate/ 
aminophenazone chromogenic system (Fossati etal., 1980). 
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2.4.4.3.1 Principle of the method: 
       Uric acid in the sample originates, by means of the coupled reactions 
described below, a coloured complex that can be measured by 
spectrophotometry. 
Uric acid + O2+ 2H2O   uricase           Alantoin+ CO2+H2O2 
2H2O2+ 4-aminoantipyrine+DCFS  Peroxidase       Quinoneimine+4H2O 
 
2.4.4.3.2 Reagents composition: 
Reagents A: 
• Phosphate        100mmol/L 
• Detergent           1.5g/L 
• Dichlorophenolsulfonate  4mmol/L 
• Uricase >        0.12 U/ml 
• Ascorbate oxidase > 5U/ml 
• Peroxidase > 1U/ml 
• 4-aminoantipyrine 0.5mmol 
• PH    7.8 
Reagent S: 
• Uric acid standard  6mg/dl (357µmol/L) 
2.4.4.3.3 Reagents preparation: 
       Reagents and standard ready to use. 
2.4.4.3.4 Procedure: 
       1- The reagents bring to room temperature. 
       2- Pipetted into labeled test tubes: 
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 Blank Standard Sample 
Distilled water 25µl - - 
standard (S) - 25µl - 
Sample - - 25µl 
Reagent (A) 1.0ml 1.0ml 1.0ml 
 
3- Mixed thoroughly and incubated the tubes for 10 min. at room 
temperature at 37C0. 
4- Measured the absorbance (A) of the standard and the sample at  
         520 nm against the blank. The colour was stable for at least 30 min. 
2.4.4.3.5 Calculation: 
       The uric acid concentration in the sample was calculated using the 
following general formula: 
 
 
2.4.4.4 Estimation of calcium (Ca++): 
        Calcium was measured according to methylthymol blue reaction 
(Gindler and King, 1972).  
2.4.4.4.1 Principle of the method: 
       Calcium in the sample reacts with methylthymol blue in alkaline 
medium forming a coloured complex that can be included in the reagent 
to avoid magnesium interference. 
2.4.4.4.2 Reagents composition: 
Reagents A: 
• Potassium cyanide   7.7mmol/L 
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• Ethanolamine           1.5mol/L 
Reagents B: 
• Methylthymol blue    0.1mmol/L 
• Hydrochloric acid     10mmol/L 
• Hydroxyquinoline    17mmol/L 
Reagents S: 
• Calcium standard      10mg/dl 
• Magnesium standard  2mg/dl 
2.4.4.4.3 Reagents preparation: 
• Standard (S): ready to use. 
• Working reagent: Mixed equal volumes of reagent A 
and B. mixed gently. Stable for 2 days at 2-8C0. 
2.4.4.4.4 Procedure: 
       1- Pipetted into labeled test tubes: 
 Blank Standard  Sample 
Standard - 10µl - 
Sample - - 10µl 
Working reagent 1.0ml 1.0ml 1.0ml 
    
       2- Mixed thoroughly and stand the tubes for 2 min. at room  
          temperature. 
       3- The absorbance (A) of the standard and the sample read at 610nm 
         against the blank. The colour was stable for at least one hour. 
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2.4.4.4.5 Calculation:  
The calcium concentration in the sample was calculated using the 
following general formula: 
 
 
2.4.4.5 Estimation of Sodium (Na+) and Potassium (K+):  
2.4.4.5.1 Principle of the method: 
       Sodium and potassium in the sample were measured by using flame 
photometer 410 in mmol/L 
2.4.4.5.2 Reagent composition: 
       All reagents are ready to use. 
•  Distilled water  10ml 
•  Sodium standard 140mmol/L 
• Potassium standard 5mmol/L 
2.4.4.5.3 Procedure: 
1- Pipetted into each test tubes 10ml distilled water (D.W) then 
pulled 100µl D.W from tubes. 
2- 100 µl sodium/potassium standard (S) added to standard tube. 
3- Then added 100 µl from the sample to the sample tube. Mixed 
thoroughly and incubated for 5min. then the concentration of 
sodium and potassium was read directly from the flame 
photometer by mmol/L. 
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2.4.4.6 Estimation of phosphate (PO4-2): 
         Phosphorus was measured according to phosphomolybdate/UV 
reaction (Tietz etal., 1999). 
2.4.4.6.1 Principle of the method: 
       Inorganic phosphorus in the sample reacts with molybdate in acid 
medium forming a phosphomolybdate complex that can be measured by 
spectrophotometry. 
2.4.4.6.2 Reagents composition: 
       Reagents A: 
• Sulfuric acid 0.36 mol/L 
• Sodium chloride 154 mmol/L 
       Reagents B: 
• Sulfuric acid  0.36 mol/L 
• Sodium chloride 154 mmol/L 
• Ammonium molybdate 3.5 mmol/L 
       Reagents S: 
• Phosphorus standard 5mg/dl (1.16 mmol/L) 
2.4.4.6.3 Reagents preparation: 
       Standard (S): Was provided ready to use 
       Working reagent: Mixed thoroughly in the proportion 7ml reagent 
A+ 3ml reagent B. Stable for 12 months at 15-30C0. 
2.4.4.6.4 Procedure: 
1- Pipetted into labeled test tubes: 
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 Reagent 
blank 
Sample 
blank 
Sample Standard 
Distilled 
water 
10µl - - - 
Sample  - 10µl 10µl - 
Standard - - - 10µl 
Reagent 
(A) 
- 1.0ml - - 
Working 
reagent 
1.0ml - 1.0ml 1.0ml 
 
            2- Mixed thoroughly and stand the tubes for 5min. at room 
              temperature. 
            3- The absorbance (A) of the sample blanks read at 340nm  
                against distilled water. 
             4- The absorbance (A) of the samples and of the standard read at 
                340nm against the reagent blank. 
2.4.4.6.5 Calculation: 
       The phosphorus concentration in the sample was calculated using the 
following general formula: 
 
2.5 Statistical analysis: 
       The data obtained were analyzed by t-test using statistical package 
for social sciences (SPSS) program. 
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    CHAPTER THREE 
RESULTS 
              The data collected in this study, was consisted of the renal 
function tests urea, creatinine, uric acid, calcium, sodium, potassium and 
phosphorus of all individuals (74 respondents) who had the range of age 
from 17 to 72 years.  
              The study   groups   divided into three   groups (groupA, B     
and C). All of them are females, group A consisted of untreated hyper 
and hypothyroidism patients, group B was consisted of treated hyper and 
hypothyroidism patients and group C served as control. 
 
3.1 The  levels  of serum  urea, creatinine, uric acid, calcium, sodium, 
      potassium  and   phosphorus  in  group  A  untreated  hyper  and               
      hypothyroidism patients: 
3.1.1 Serum  urea  concentration levels  in group A compared  to the 
         control:    
               The level means of urea in serum of euthyroid adult females are 
19.13+2.In hyper subjects, the level of urea increased very highly 
significant (P< 0.001) in all subjects studied to 31.29 (tables 1, 3 and 
fig.5). While in hypo subjects the concentration of urea also increased 
highly significant (P< 0.01) in all subjects studied to 24.3 (table 1, 4 and 
fig.5). But the concentration of urea (24.3) decreased significantly       
(P< 0.05) in hypothyroidism compare to hyperthyroidism (31.29) in the 
same group. 
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 Table 1:   The means and   standard deviation (SD) of serum levels of 
                 urea,  creatinine,  uric acid,  calcium,  sodium,   potassium 
                 and phosphorus concentrations of  all patients  and control           
               groups.  
        Group A 
        untreated 
      (mean+SD) 
           n =27 
Group B 
treated 
       (mean+SD) 
            n =32 
Parameters 
hypo hyper hypo hyper 
Group  
C 
control 
(mean+
SD) 
n =15 
Urea mg/dl 24.3+4.4** 31.3+9.3*** 30.8+10.5*** 32.4+15.7** 19.1+2 
Creatinine 
mg/dl 
0.52+0.1*** 0.62+0.2 0.61+0.1 0.67+0.2 0.65+ 
0.05 
Uric acid 
mg/dl 
4.6+0.5* 5.1+0.6 5.1+0.6 5.6+1.4 5.0+0.2
Ca+2   
mg/dl 
8.8+0.5 9.3+0.6** 8.9+0.7 9.5+0.6*** 8.8+0.2
 
Na+    
mmol/l 
138.3+1.5 138.7+2.2 136.2+3.5 140.3+4.7* 137.5+
1.6 
K+  
mmol/l 
3.8+0.2 4.4+0.7* 3.8+0.2 5.3+1.0*** 3.9+0.2
Po--4 
Mg/dl 
4.6+0.5 4.9+0.4 4.0+0.4*** 5.2+0.4** 4.8+0.3
Degree of significant: 
 * ≡ P< 0.05 significant 
** ≡ P <0.01 highly significant. 
*** ≡ P<0.001 very highly significant. 
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3.1.2 Serum creatinine concentration levels in group A compared to 
the control: 
             Tables (1, 3) and fig. (6), show that the mean of serum creatinine 
level of euthyroid adult females are 0.647+ 0.05, while in hyper subjects 
are 0.624. There was no significant difference in the level of creatinine, 
but table (1, 4) and fig. (6) show that the concentration of serum 
creatinine in hypothyroidism subjects decreased very highly significant 
(P< 0.001) in all subjects to 0.52.                                                                                          
3.1.3 Serum uric acid concentration levels in group A compared to 
the control:  
             Tables (1,3) and fig.(7), show that the mean of the concentration 
of serum uric acid of euthyroid adult females are 4.967+0.24, while in 
hyper subjects are 5.059, so there was non-significant difference.     
Table (1, 4) and fig. (7), show that the concentration levels of serum uric 
acid in hypothyroidism subjects decreased significantly (P<0.05) in all 
subjects studied to 4.56. 
3.1.4 Serum calcium (Ca++) concentration levels in group A 
compared to the control: 
             Tables (1, 3) and fig. (8), show that the mean levels of serum 
calcium concentration of euthyroid adult females are 8.787+0.18. In 
hyper subjects, the levels of calcium increased highly significant  
(P<0.01) in all subjects studied to 9.30, while in hypo subjects the mean 
of calcium concentration is 8.81 show non-significant difference      
(table 1, 4 and fig. 8). 
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3.1.5 Serum sodium (Na+) concentration levels in group A compared 
to the control: 
             Tables (1, 3, 4) and fig. (9), show that the mean levels of sodium 
concentration of euthyroid adults females, hyper subjects and hypo 
subjects are 137.47+1.6, 138.71 and 138.30 mmol/L respectively. 
Statistically there was non-significant difference in all subjects studied. 
3.1.6 Serum potassium (K+) concentration levels in group A 
compared to the control: 
             Tables (1, 3) and fig. (10), show that the mean levels of serum K+ 
concentration of euthyroid adult females are 3.86+0.18. In hyper 
subjects, the levels of K+ increased significantly (P<0.05) to 4.36, while 
in hypo subjects (table 1,4) the mean of K+ concentration is 3.76 show 
there is non-significant difference compare to euthyroid subjects. 
3.1.7 Serum phosphorus (Po--4) concentration levels in group A 
compared to the control: 
            Tables (1, 3, 4) and fig. (11), show that the mean levels of (Po4--) 
concentration of euthyroid, hyper and hypothyroidism adult females are 
4.79+0.27, 4.95 and 4.62mg/dl respectively. There was non-significant 
difference in all subjects studied in group A. 
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 Fig (5) the levels of serum urea concentration in group (A) compared 
to the control group (C) 
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 Fig (6) the levels of serum creatinine concentration in group (A) 
 compared to the control group (C) 
group (A) with control
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Fig (7) the levels of serum uric acid concentration in group (A) 
compared to the control group (C) 
group (A) with control
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Fig (8) the levels of serum calcium (ca) concentration in group (A) 
compared to the control group (C)                     
 
 
 
 
 
 
 
 
                                          
 
 
 
Fig (9) the levels of serum sodium (Na) concentration in group (A)      
compared to the control group (C)                                     
group (A) with control
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 Fig (10) the levels of serum potassium (K) concentration in group                
(A) compared to the control group (C)                                  
group (A) with control
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Fig (11) the levels of serum phosphorus (PO4) concentration in 
group (A) compared to the control group (C) 
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3.2 The levels of serum urea, creatinine, uric acid, calcium,      
sodium, potassium and phosphorus  in  group B treated hyper      and 
hypothyroidism patients compared to control: 
3.2.1 Serum urea concentrations level in group (B) compared to      
the control: 
             The mean of urea levels in serum of euthyroid adult females are 
19.13+2. In hyper subjects, the level of urea increased highly significant 
(P<0.01) in all subjects studied in group B (treated) to 32.38                
(tables 1, 5 and fig.12). While in treated hypo subjects the concentration 
of urea also increased very highly significant (P<0.001) to 30.81 in the 
same group compared to the control (table 1, 6 and fig. 12). 
3.2.2 Serum creatinine concentrations level in group (B) compared to 
the control: 
             Tables (1, 5, 6 and fig.13), show that the mean levels of serum 
creatinine of euthyroid, hyper and hypothyroidism adult females are 
0.647+0.05, 0.669 and 0.606 mg/dl respectively. Statistically there is 
non-significant difference in all subjects studied in group B. 
3.2.3 Serum uric acid concentrations level in group (B) compared to 
the control: 
             Tables (1, 5, 6 and fig. 14), show that the mean levels of serum 
uric acid of euthyroid, hyper and hypothyroidism females are 
4.967+0.24, 5.55 and 5.09 mg/dl respectively. There is non-significant 
difference in all subjects studied in group B. 
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3.2.4 Serum calcium concentrations level in group (B) compared to 
the control: 
             Tables (1, 5) and fig. (15), show that the mean levels of serum 
calcium concentration of euthyroid adult females are 8.787+0.18. In 
hyper subjects, the levels of calcium increased very highly significant 
(P<0.001) in all subjects studied to 9.53, while in hypo subjects the mean 
of calcium concentration is 8.85, show that there is no significant 
difference (tables 1, 6 and fig. 15). 
3.2.5 Serum sodium concentrations level in group (B) compared to 
the control: 
             Tables (1, 5) and fig. (16), show that the mean levels of serum 
sodium concentration of euthyroid adult females are 137.47+1.64. In 
hyper subjects, the levels of sodium increased significantly (P<0.05) to 
140.25 mmol/L. While in hypo subjects the mean of sodium 
concentration is 136.19 mmol/L, show that there is non-significance 
different (tables 1, 6 and fig. 16). 
3.2.6 Serum potassium concentrations level in group (B) compared to 
the control: 
             Tables (1, 5) and fig. (17), show that the mean levels of serum 
potassium concentration of euthyroid adult females are 3.86+0.18. In 
hyper subjects the levels of potassium increased very highly significant 
(P<0.001) to 5.28 mmol/L, while in hypo subjects (tables 1, 6), the mean 
potassium concentration is 3.84mmol/L show that there is non-significant 
difference compare to the euthyroid subjects. 
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3.2.7 Serum phosphorus concentrations level in group (B) compared 
to the control: 
             Tables (1, 5, 6) and fig. (18), show that the mean levels of 
phosphorus concentration of euthyroid, hyper and hypothyroidism adult 
females are 4.79+0.27, 5.16 and 3.99 mg/dl respectively. In hyper 
subjects, the levels of phosphorus increased highly significant (P<0.01) 
while in hypo subjects the concentration of phosphorus decreased very 
highly significant (P<0.001) compared to the control. 
 
Fig (12) the levels of serum urea concentration in group (B)    
compared to the control group (C) 
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Fig (13) the levels of serum creatinine concentration in group (B) 
           compared to the control group (C)                                
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Fig (14) the levels of serum uric acid concentration in group (B) 
            compared to the control group (C) 
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Fig (15) the levels of serum calcium (ca) concentration in group (B)       
compared to the control group (C)  
group (B) with control
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Fig (16) the levels of serum sodium (Na) concentration in group (B) 
compared to the control group (C) 
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Fig (17) the levels of serum potassium (K) concentration in group (B) 
compared to the control group (C)              
group (B) with control
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Fig (18) the levels of serum phosphorus (PO4) concentration in     
group (B) compared to the control group (C)     
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CHAPTER FOUR 
DISCUSSION 
4.1 Thyroid diseases: 
             In the present study, 33 patients were considered as severely 
hyperthyroidism patients (T4>250nmol/L), 17 new cases and 16 cases 
under treatment. While 26 patients were considered as severely 
hypothyroidism patients (TSH>50 mIU/ml), 10 new cases and 16 cases 
under treatment. 
             This reflect that the number of patients with hyperthyroidism was 
high than that of patients with hypothyroidism, in particular the new 
cases of hypothyroidism. This might be due to the slow appearance of 
symptoms hypothyroidism on an affected person. The symptoms are 
often present for years before the diagnosis is made and because of their 
non-specific and vague nature are often attributed to non-organ causes. 
The patient usually has no complaints and the diagnosis is made almost 
accidentally (Weatherall et al., 1984). 
4.2 The effect of thyroid dysfunction on the serum urea:  
             Tables (3, 4, 5, 6), showed that the level of urea increased 
significantly (P<0.05) in all patients of thyroid disease in the present 
study compared to the euthyroid subjects. This support the idea has been 
suggested in hyperthyroidism patients with Graves’ disease, the blood 
urea nitrogen (BUN) increased. In contrast, in hypothyroidism patients, 
the increase of serum urea may be due to other reasons have no relation 
to the effect of thyroid disease. 
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             These reasons might be due either to increased protein 
catabolism or impaired kidney function. Increased protein catabolism 
results from a really big protein meal, severe stress (myocardial 
infarction, high fever, etc…) and upper GI bleeding (blood being 
digested and absorbed), another reason might be dehydration, 
hemorrhage, shock and congestive heart failure (Ed, 2007) 
4.3 Serum creatinine levels: 
             Tables (3, 4, 5, 6), showed that there is no significant effect on 
creatinine levels in all patients of thyroid disease in the present study 
compared to euthyroid subjects except in untreated hypothyroidism, there 
is very highly significant decrease (P<0.001) on creatinine levels and this 
decrease unrelated to thyroid or renal dysfunctions, may be due to other 
reasons. The reasons decreased creatinine levels may be seen in elderly, 
persons with small stature, decreased muscle mass or inadequate dietary 
protein. Muscle atrophy can also result in decreased serum creatinine 
levels (rnceus.com/renal/renal creat.html). 
These finding do not support the idea that suggested the effect of thyroid 
disease on renal function. 
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Table 2: Factors decreasing serum creatinine concentration* 
Factor  Mechanism/comment 
Age  Reduction in creatinine 
generation due to age-related 
decline in muscle mass 
Female sex Reduced creatinine generation 
due to reduced muscle mass 
Vegetarian diet Decrease in creatinine generation 
Malnutrition/muscle 
wasting/amputation 
Reduced creatinine generation 
due to reduce muscle 
mass+reduced protein uptake 
*(levey, 1993) 
4.4 Serum uric acid levels: 
             Tables (3, 4, 5, 6) showed that there is non-significant effect on 
serum uric acid in all patients of thyroid disease in the present study 
compared to euthyroid subjects except untreated hypothyroid patients, 
there is a significant decrease (P<0.05) on serum uric acid. This result is 
disagreement with the study reported by Giordano, et al (2001) who 
studied hyperuricemia and gout in thyroid endocrine disorders; they 
reported that a significant increase of both hyperuricemia and gout was 
found in the hypothyroid, and of hyperuricemia in the hyperthyroid 
patients. In hyperthyroidism the hyperuricemia is due to the increase in 
urate production, while in hypothyroidism the hyperuricemia is 
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secondary to a decreased renal plasma flow and impaired glomerular 
filteration. Our findings confirm the decrease of serum uric acid in 
untreated hypothyroid patients related to non thyroid disorders may be to 
other reasons. These might be due to the increased renal uric acid 
clearance which associated with hypoparathyoidism, primary 
aldosteronism and in appropriate secretion of antidiuretic hormone 
(Yokogoshi et al., 1996). Another reason might be during acute gouty 
arthritis (Hara et al., 2002). 
4.5 Serum calcium and phosphate concentrations level: 
             Tables (3, 5) showed that there is a significant increase (P<0.05) 
on serum Ca++ levels in all patients of hyperthyroidism in the present 
study compared to the euthyroid subjects. Where as tables (5, 6) showed 
that there is a highly significant increase (P<0.01) on serum PO--4 levels 
with treated hyperthyroid patients and very highly significant decrease 
(P<0.001) with hypothyroid patients under treatment compared to 
euthyroid subjects in the present study. 
             These observations in agreement with the study findings 
suggested by (Se et al., 2007) who reported that the serum calcium and 
phosphate were significantly higher in Graves’ disease. Also Poula, 
(2003) demonstrated that hypophosphatemia might be caused by 
hypomagnesaemia and hypokalemia. Sever burns, alcoholism, diabetic 
ketoacidosis, kidney diseases, hyperparathyroidism, hypothyroidism, 
Cushing's syndrome; malnutrition, hemodialysis, vitamin D deficiency 
and prolonged diuretic therapy can also diminish blood phosphate levels. 
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4.6 Serum sodium (Na+) and potassium (K+) concentrations level: 
             The present study showed that there is non-significant effect of 
thyroid disease on serum Na+ levels compared to euthyroid subjects 
except the patients under treatment of hyperthyroidism, they have 
significant increase (P<0.05) compared to the euthyroid subjects      
(table 5). Our findings confirm the increase of serum Na+ levels in 
hyperthyroid patients under treatment might be related to other reasons 
instead of thyroid disease. Hypernatremia can be caused by inadequate 
water intake, excessive fluid loss (i.e., diabetes insipidus, kidney disease, 
severe burns, prolonged vomiting or diarrhea), or sodium retention 
(caused by excessive sodium intake or aldosteronism). In addition, 
certain drugs, including loop diuretics, corticosteroids and 
antihypertensive medications may cause elevated sodium levels     
(Paula, 2003). 
             Tables (3, 5) showed that there is a significant increase (P<0.05) 
on serum K+ levels in all patients of hyperthyroidism in the present study 
compared to the euthyroid subjects. Our findings do not support the idea 
that suggested the effect of thyroid disorder on serum K + levels. This 
hyperkalemia might be due to kidney dysfunction, diseases of the adrenal 
gland, potassium shifting out of cells into the blood circulation and 
medications (Melissa, 2007). 
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CONCLUSION 
            
       Our findings confirm that there is no direct effect of thyroid disease 
on renal function of Sudanese females’ patients with thyroid dysfunction. 
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APPENDICES 
   Table 3: T-test for independent samples between group A 
            untreated hyperthyroidism patients and the control. 
             t-test for Equality of Means  
         t         df Sig.(2-tailed)     Mean 
Difference 
Urea Mg/dl 
 
 
 
Equal variances 
assumed 
Equal variances 
not assumed 
    4.956 
 
    5.257 
30 
 
17.658 
.000 
 
.000 
12.16 
 
12.16 
Creatinine 
Mg/dl  
Equal variances 
assumed 
Equal variances 
not assumed 
   -.560 
 
   -.590 
30 
 
20.058 
.580 
 
.562 
-2.314 
   E-02 
-2.314   E-
02 
Uricacid Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
   .596 
 
   .623 
30 
 
22.596 
.556 
 
.540 
9.216E-02 
 
9.216E-02 
Ca   Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
   3.148 
 
   3.321 
30 
 
19.298 
.004 
 
.004 
.513 
 
.513 
Na   Mmol/l Equal variances 
assumed 
Equal variances 
not assumed 
   1.800 
 
   1.832 
30 
 
29.358 
.082 
 
.077 
1.24 
 
1.24 
K   Mmol/l Equal variances 
assumed 
Equal variances 
not assumed 
   2.697 
 
    2.852 
30 
 
18.639 
.011 
 
.010 
.499 
 
.499 
Po4    Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
   1.167 
 
   1.200 
30 
 
27.308 
.253 
 
.241 
.154 
 
.154 
     Degree of significant (sig. <0.05) 
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        Table 4: T-test for independent samples between group A: 
                untreated hypothyroidism patients and group C  
               (control).  
      t-test for Equality of Means  
   t     df  Sig.(2-tailed)    Mean 
Difference 
Urea Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
3.986 
 
3.466 
   23 
 
11.471 
      .001 
 
      .005 
     5.17 
 
     5.17 
Creatinine 
Mg/dl 
Equal variances 
assumed 
Equal variances 
not assumed 
-4.075 
 
-3.591 
   23 
 
12.035 
      .000 
 
      .004 
   -.127 
 
   -.127 
Uricacid 
Mg/dl 
Equal variances 
assumed 
Equal variances 
not assumed 
-2.655 
 
-2.322 
   23 
 
11.707 
      .014 
 
      .039 
    -.407 
 
   -.407 
Ca Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
.157 
 
.132 
   23 
 
10.437 
      .877 
 
      .897 
2.333E-02 
 
2.333E-02 
Na Mmol/l Equal variances 
assumed 
Equal variances 
not assumed 
1.287 
 
1.313 
   23 
 
20.696 
      .211 
 
      .204 
     .83 
 
     .83 
K Mmol/l Equal variances 
assumed 
Equal variances 
not assumed 
-1.330 
 
-1.346 
   23 
 
20.229 
      .197 
 
      .193 
-1.000E-01 
 
-1.000E-01 
PO4 Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
-1.167 
 
-1.054 
23 
 
13.202 
      .255 
 
      .311 
   -.173 
 
   -.173 
 Degree of significant (sig. < 0.05) 
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 Table 5 : T-test for independent samples between group B treated 
              hyperthyroidism patients and the control. 
t-test for Equality of Means  
      t       df Sig.(2-tailed)   Mean 
Difference 
Urea 
Mg/dl 
Equal variances 
assumed 
Equal variances 
not assumed 
3.233 
 
3.339 
        29 
 
 15.515 
     .003 
 
      .004 
13.24 
 
13.24 
Creatinine 
Mg/dl 
Equal variances 
assumed 
Equal variances 
not assumed 
 .416 
 
 .429 
        29 
 
  17.136 
      .680 
 
      .674 
2.208E-02  
 
2.208E-02 
Uricacid 
Mg/dl 
Equal variances 
assumed 
Equal variances 
not assumed 
1.604 
 
1.655 
        29 
 
  15.988 
      .120 
 
       .117 
.583 
 
.583 
Ca Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
4.796 
 
4.928 
       29 
 
  18.261 
       .000 
 
       .000 
.745 
 
.745 
 
Na Mmol/l Equal variances 
assumed 
Equal variances 
not assumed 
2.178 
 
2.235 
       29 
 
   18.843 
       .038 
 
       .038 
2.78 
 
2.78 
K Mmol/l Equal variances 
assumed 
Equal variances 
not assumed 
5.205 
 
5.370 
       29 
 
  16.044 
        .000  
 
        .000   
1.421 
 
1.421 
Po4 Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
2.820 
 
2.860 
      29 
 
  25.761 
        .009   
 
         .008  
.369 
 
.369 
   Degree of significant (sig. <0.05) 
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Table 6: T-test for independent samples between group B treated 
               hypothyroidism patients and the control. 
                    t-test for Equality of Means  
        t        df Sig.(2-tailed)     Mean 
Difference 
Urea Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
4.237 
 
4.370 
29 
 
16.154 
.000 
 
.000 
11.68 
 
11.68 
Creatinine 
Mg/dl 
Equal variances 
assumed 
Equal variances 
not assumed 
-1.219 
 
-1.247 
29 
 
20.810 
.233 
 
.226 
-4.042E-02 
 
-4.042E-02 
Uric acid 
Mg/dl 
Equal variances 
assumed 
Equal variances 
not assumed 
.714 
 
.733 
29 
 
19.423 
.481 
 
.473 
.127 
 
.127 
Ca Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
.351 
 
.361 
29 
 
17.377 
.728 
 
.722 
6.333E-02 
 
6.333E-02 
Na Mmol/l Equal variances 
assumed 
Equal variances 
not assumed 
-1.292 
 
-1.319 
29 
 
21.634 
.207 
 
.201 
-1.28 
 
-1.28 
K Mmol/l Equal variances 
assumed 
Equal variances 
not asumed 
-.208 
 
-.209 
29 
 
28.073 
.837 
 
.836 
-1.625E-02 
 
-1.625E-02 
Po4 Mg/dl Equal variances 
assumed 
Equal variances 
not assumed 
-5.962 
 
-6.050 
29 
 
25.297 
.000 
 
.000 
-.800 
 
-.800 
Degree of significant (sig. <0.05)  
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